. 2013 Dec 3;170(3):451–459. doi: 10.1530/EJE-13-0797
This work is licensed under a Table 1.
Characteristics (mean and s.d., *median, and interquartile range) at baseline and after 3 months of metformin or liraglutide or combined treatment.
| MET (n=14) | LIRA (n=11) | COMBI (n=11) | P values | ||||
|---|---|---|---|---|---|---|---|
| Pretreatment | Posttreatment (after 3 months) | Pretreatment | Posttreatment (after 3 months) | Pretreatment | Posttreatment (after 3 months) | ||
| Age (years) | 31.3±9.4 | 31.5±6.4 | 31.1±5.1 | NS | |||
| BMI (kg/m2) | 36.6±3.5 | 36.1±3.8 | 39.3±4.2 | 37.9±4.0 | 37.6±5.1 | 35.3±5.5 | T<0.001; C vs M<0.001 |
| Weight (kg) | 103.2±6.3 | 102±6.8 | 108.9±15.1 | 105.1±13.8 | 105.5±20.6 | 99±21.2 | T<0.001; C vs M<0.001 |
| Waist circumference (cm) | 122.3±7.0 | 120.7±7.8 | 124.9±9.9 | 121.7±9.6 | 121.9±17.7 | 116.4±18.4 | T=0.049; C vs M=0.050 |
| BP systolic (mmHg) | 121.9±13.1 | 116.8±14.6 | 123.3±15.4 | 114.9±12.6 | 125.0±13.0 | 126.7±18.2 | NS |
| BP diastolic (mmHg) | 74.1±12.2 | 70.2±9.4 | 77.2±15.6 | 71.8±9.9 | 80.0±6.6 | 79.9±7.8 | NS |
| Total body % fat (%) | 45.6±4.7 | 44.5±4.7 | 47.1±2.7 | 45.5±3.0 | 44.8±3.7 | 43.3±3.5 | NS |
| VAT mass (g) | 808.8±229.3 | 732.5±172.1 | 840.4±346.4 | 762.3±296.8 | 768.2±277.5 | 746.5±273.2 | NS |
| VAT volume (cm3) | 874.3±247.9 | 792.1±186.0 | 908.6±374.6 | 824.1±321.0 | 830.1±299.4 | 806.9±295.1 | NS |
| VAT area (cm2) | 167.7±47.6 | 151.9±35.6 | 174.3±71.9 | 158.1±61.6 | 159.4±57.6 | 154.9±56.8 | NS |
| Menstrual cycles (n/month) | 0.7±0.4 | 0.6±0.4 | 0.6±0.3 | 0.8±0.3 | 0.5±0.3 | 0.7±0.3 | NS |
| HOMA-IR score | 3.8 (3.8)* | 2.5 (2.4)* | 2.4 (2.3)* | 2.1 (2.0)* | 1.7 (4.9)* | 2.1 (2.9)* | NS |
| Glu 0 min OGTT (mmol/l) | 5.1 (0.9)* | 5.5 (0.5)* | 5.1 (1.2)* | 4.7 (1.0)* | 5.1 (0.2)* | 4.6 (1.0)* | NS |
| Glu 120 min OGTT (mmol/l) | 7.3±2.6 | 7.6±2.0 | 7.1±1.9 | 5.8±1.3 | 7.7±1.8 | 5.8±1.3 | T=0.009; C vs M=0.006 |
| Insulin 0 min OGTT (mU/l) | 12.3 (13.3)* | 12.7 (8.3)* | 11.1 (9.6)* | 9.4 (9.6)* | 5.7 (11.8)* | 9.4 (11.7)* | NS |
| Insulin 120 min OGTT (mU/l) | 79.0 (112.1)* | 86.9 (75.3)* | 59.2 (97.0)* | 68.4 (88.1)* | 56.8 (73.2)* | 55.8 (50.4)* | NS |
| Cholesterol (mmol/l) | 4.7±0.6 | 4.6±0.4 | 4.9±0.7 | 4.7±0.7 | 5.3±1.1 | 4.6±0.8 | NS |
| HDL cholesterol (mmol/l) | 1.1±0.2 | 1.2±0.2 | 1.1±0.3 | 1.1±0.2 | 1.3±0.4 | 1.1±0.4 | NS |
| LDL cholesterol (mmol/l) | 2.9±0.6 | 2.9±0.5 | 3.2±0.8 | 3.1±0.5 | 3.4±0.8 | 2.9±0.8 | NS |
| TG (mmol/l) | 1.6 (0.5)* | 1.3 (0.5)* | 1.4 (1.1)* | 1.1 (1.4)* | 1.4 (0.4)* | 1.4 (0.5)* | NS |
| Total testosterone (nmol/l) | 1.7±1 | 1.5±0.9 | 1.8±1.1 | 2.2±1.4 | 2.1±1.3 | 1.6±0.7 | NS |
| Free testosterone (pmol/l) | 5.7±3.2 | 5±3.3 | 7.4±2.8 | 8±3.9 | 7.6±3.7 | 5.6±2.7 | NS |
| SHBG (nmol/l) | 20.0 (17.0)* | 24.0 (11.0)* | 16.0 (11.0)* | 21.0 (12.5)* | 36.5 (27.8)* | 44.0 (31.0)* | NS |
| DHEAS (μmol/l) | 6.2±3.2 | 5.8±3.6 | 4.3±2.2 | 4.6±3.2 | 5.7±2.1 | 5.3±2.4 | NS |
| Androstenedione (nmol/l) | 7.1±2.7 | 7.9±3.1 | 9±2.9 | 10.9±5.3 | 11.5±4.8 | 9.3±3.3 | T=0.029; C vs L=0.030 |
For P values, T, overall effect after all treatments; M, MET; L, LIRA; C, COMBI; NS, not significant; BP, blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; Glu, glucose; TG, triglyceride; SHBG, sex hormone-binding globulin; VAT, visceral adipose tissue. Values of androgens in the healthy matched population: total testosterone, 0.3–3.5 nmol/l; free testosterone, 0.14–7.0 pmol/l; SHBG, 18–114 nmol/l; DHEAS, 3.6–12.9 μmol/l; androstenedione, 0.7–10.8 nmol/l.